Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Net Margin (2023 - 2025)

Historic Net Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 445.67%.

  • BioLineRx's Net Margin fell 3695600.0% to 445.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 1192400.0%. This contributed to the annual value of 39.01% for FY2024, which is 9511000.0% up from last year.
  • BioLineRx's Net Margin amounted to 445.67% in Q3 2025, which was down 3695600.0% from 666.78% recorded in Q2 2025.
  • BioLineRx's 5-year Net Margin high stood at 50.74% for Q4 2024, and its period low was 1376.34% during Q3 2023.
  • For the 3-year period, BioLineRx's Net Margin averaged around 459.55%, with its median value being 386.78% (2025).
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 13002400bps in 2024, then tumbled by -7161500bps in 2025.
  • BioLineRx's Net Margin (Quarter) stood at 327.89% in 2023, then skyrocketed by 115bps to 50.74% in 2024, then plummeted by -978bps to 445.67% in 2025.
  • Its Net Margin was 445.67% in Q3 2025, compared to 666.78% in Q2 2025 and 772.94% in Q1 2025.